Psoriasis, atopic dermatitis studies top dermatology reads for week

Study findings on treatments for psoriasis and atopic dermatitis presented at the recent European Academy of Dermatology and Venereology Congress in Vienna were among the most-read articles of the past week on Healio.com/Dermatology.

Other widely read articles included research validating a 10-class facial laxity rating scale, demonstrating it may be used as a reliable tool for chronological assessment or treatment-related laxity of the face and neck:

Cosentyx demonstrates efficacy in skin clearance for psoriasis over 4 years

Novartis has announced that patients with moderate-to-severe plaque psoriasis maintained skin clearance after 4 years of treatment with Cosentyx, according to research presented at the European Academy of Dermatology and Venereology Congress in Vienna.

“[Study results] show that Cosentyx [secukinumab] keeps working year-on-year, maintaining high levels of skin clearance with a favorable safety profile,” Vasant Narashimhan, global head, Drug Development and chief medical officer of Novartis, stated in a press release. Read more

Facial laxity rating scale validated

The 10-class facial laxity rating scale was validated by physician investigators, demonstrating it may be used as a reliable tool for chronological assessment or treatment-related laxity of the face and neck, according to recently published study results.

“Considering there is an absence of a validated scale to accurately assess the firmness-laxity spectrum of the face and neck with widely accepted classification and terminology, [the goal] was to create a simple, accurate and reproducible assessment tool: the [facial laxity rating (FLR)] scale,” Hector G. Leal Silva, MD, PhD, of the division of health sciences, University of Monterrey, Mexico, wrote. Read more

Tildrakizumab demonstrates efficacy in moderate-to-severe plaque psoriasis

Tildrakizumab, an investigational IL-23p19 inhibitor, demonstrated efficacy in treating moderate-to-severe chronic plaque psoriasis in two phase 3 trials at week 12, with continued improvement through week 28, according to data presented at the European Academy of Dermatology and Venereology Congress in Vienna.

“For patients with psoriasis, their condition is always top of mind and they struggle on a daily basis with the often debilitating effects of this chronic condition,” study researcher Kristian Reich, MD, professor of dermatology at the Georg-August-University Göttingen and inflammation specialist at the Dermatologikum Hamburg in Germany, stated in a press release from Sun Pharma. Read more

Dupixent shows efficacy in treating atopic dermatitis

Adults with atopic dermatitis who were treated with Dupixent in two identical phase 3 trials experienced improvement in severity of disease and in symptoms including pruritus, anxiety and depression, according to study results recently published in The New England Journal of Medicine.

“These results support a growing body of evident for Dupixent as a potential new treatment option for patients with moderate-to-severe atopic dermatitis who are struggling to control their disease,” researcher Eric L. Simpson, MD, MCR, Oregon Health and Science University, stated in a press release form Sanofi and Regeneron Pharmaceuticals. Read more

Atopic dermatitis negatively impacts patients socially and psychologically, survey reports

Adults with moderate-to-severe atopic dermatitis reported that the disease impacted their lives socially and psychologically, according to survey results.

There were 505 American adults with moderate-to-severe atopic dermatitis who participated in an online survey conducted by Harris Poll on behalf of Sanofi Genzyme and Regeneron Pharmaceuticals, according to a press release. The results were released as part of a national awareness campaign during Eczema Awareness Month. Read more